RANKL

Synonyms

Osteoclast differentiation factor, TRANCE, TNFSF11, TNF-related activation-induced cytokine, Tumor necrosis factor ligand superfamily member 11, CD254, TNF Superfamily Member 11, Osteoprotegerin Ligand, Receptor Activator Of Nuclear Factor Kappa B Ligand, Tumor Necrosis Factor Superfamily Member 11, CD254 Antigen, HRANKL2, TNLG6B, OPTB2, SOdf, RANK Ligand, ODF, RANKL, OPGL, Tumor Necrosis Factor (Ligand) Superfamily, Member 11, Receptor Activator Of Nuclear Factor Kappa-B Ligand, Tumor Necrosis Factor Ligand 6B,

Description

Receptor activator of nuclear factor kappa-Β ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is a protein that in humans is encoded by the TNFSF11 gene. It is a cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK.Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy . Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation.

KO Status

F0

Drug Information

Launched drugs: 18
Drug in clinical trials: 1
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Recombinant aiti-RANKL human monoclonal antibody (Shanghai Hansoh)

IND

Shanghai Hansoh Biomedical Co Ltd

Neoplasms

Denosumab biosimiliar (Celltrion)

CT-P41

Celltrion

Denosumab

AMG-162, NSC-744010

Approved

Amgen Inc

Bone metastases, Solid tumours, Cataract, Kidney Neoplasms, Hematologic Neoplasms, Head and Neck Neoplasms, Endocrine Gland Neoplasms, Osteoporosis, Bone Diseases, Metabolic, Parathyroid Neoplasms, Carcinoma, Osteoporosis, Postmenopausal, Colonic Neoplasms, Hodgkin Disease, Arthritis, Rheumatoid, Kidney Diseases, Hypercalcemia, Multiple Myeloma, Osteogenesis Imperfecta, Prostatic Neoplasms, Breast Neoplasms, Giant Cell Tumors, Giant Cell Tumor of Bone, Bone Neoplasms, Fractures, Bone, Thyroid Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Lymphoma, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung

Recombinant aiti-RANKL human monoclonal antibody (Kunming Pharmaceutical)

IND

Kpc Pharmaceuticals Inc

Neoplasms

Recombinant anti-RANKL human monoclonal antibody (Salubris)

IND

Shenzhen Salubris Pharmaceuticals Co Ltd

Neoplasms

Denosumab biosimilar (Intas Biopharmaceuticals)

Phase 3 Clinical

Intas Biopharmaceuticals

Osteoporosis, Postmenopausal

Recombinant human anti-RANKL antibody (Alphamab)

KN-012

Phase 3 Clinical

Suzhou Alphamab Co Ltd

Osteoporosis, Postmenopausal

Recombinant human anti-RANKL antibody (Jiangsu T-mab BioPharma)

MW031, MW032, TK-006

Phase 3 Clinical

Jiangsu T-Mab Biopharma

Bone metastases, Osteoporosis, Neoplasms, Osteoporosis, Postmenopausal, Breast Neoplasms, Bone Neoplasms

Denosumab biosimilar (Qilu Pharma)

QL-1206

Phase 3 Clinical

Qilu Pharmaceutical Co Ltd

Bone metastases, Osteoporosis, Postmenopausal

Denosumab biosimilar (Boan Biopharma/Luye Pharma)

LY-06006, LY-01011

Phase 3 Clinical

Shandong Boan Biotechnology Co Ltd, Luye Pharma

Bone metastases, Osteoporosis, Osteoporosis, Postmenopausal, Bone Neoplasms, Neoplasm Metastasis

Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical)

Phase 3 Clinical

Qilu Pharmaceutical Co Ltd

Neoplasms, Osteoporosis, Postmenopausal

Denosumab biosimilar (Sandoz)

GP-2411

Phase 3 Clinical

Novartis Pharma Ag, Sandoz

Osteoporosis, Postmenopausal

Denosumab biosimilar (AryoGen)

Phase 3 Clinical

Aryogen Biopharma

Osteoporosis, Osteoporosis, Postmenopausal

JMT103

JMT-103

Phase 2 Clinical

Shanghai Jinmante Biological Technology Co Ltd

Bone metastases, Osteoporosis, Hypercalcemia, Giant Cell Tumors, Osteoma

AP-002

LX-001, AP-003, AP-002

Phase 2 Clinical

Altum Pharmaceuticals

Neoplasms

Recombinant human anti-RANKL antibody(Shanghai Henlius Biotech)

HLX14

Phase 1 Clinical

Shanghai Henlius Biotech Co Ltd

Osteoporosis, Postmenopausal

Recombinant human anti-RANKL antibody (Hisun Pharma)

HS629

Phase 1 Clinical

Zhejiang Hisun Pharmaceutical Co Ltd

Neoplasms

Recombinant human anti-RANKL momoclonal antibody (Hualan Biological Engineering)

Phase 1 Clinical

Hualan Genetic Engineering Co Ltd

Solid tumours, Osteoporosis, Postmenopausal

LZM-004

LZM-004

Phase 1 Clinical

Livzon（Group） Pharmaceutical Factory

Neoplasm Metastasis

Recombinant human anti-RANKL antibody (Innovent Biologics)

IBI-307

Phase 1 Clinical

Innovent Biologics (Suzhou) Co Ltd

Osteoporosis

What's Next for KO Library?

Please stay tuned for the latest progress of KO Library. We are open to co-development programs of antibody therapeutics using our RenMab™-target-knockout mice.
Please contact our team if you are interested in learning more about KO Library or partnering opportunities.